Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 18Thoracic 2Sarcoma 2Other solid neoplasm 2Other hematologic neoplasm 1Dermatologic 1

Conditions

Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1

Interventions

Peripheral Blood Stem Cell Transplantation 42fludarabine phosphate 37Cyclophosphamide 36Mycophenolic Acid 28Whole-Body Irradiation 26Cyclosporine 25Busulfan 25Tacrolimus 22Antilymphocyte Serum 21Methotrexate 16Filgrastim 16Etoposide 15Methylprednisolone 13Melphalan 13Radiotherapy 12Flow Cytometry 11Psychiatric Rehabilitation 10Therapeutics 9Rituximab 9Polymerase Chain Reaction 8Bortezomib 8Gemcitabine 7Cord Blood Stem Cell Transplantation 7sargramostim 6Vorinostat 6Sirolimus 6tanespimycin 5Transplantation 5Thiotepa 5Carboplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × tazemetostat × Dermatologic × Clear all
NCT05627245 2026-05-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

National Cancer Institute (NCI)

Phase 1 Active not recruiting
48 enrolled
DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡